Análisis Argos
RVTY
RVTYCara
Revvity, Inc. · Healthcare
US$ 113.76
precio al 2026-07-04
Valor justo Argos*
US$ 59–66
vs. su valor justo
90% por encima
Score Argos
37/100
LA RESPUESTA
El mercado le pide crezca 22.4% al año — más de lo que ha demostrado (1.4%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
Sin recompensas destacadas.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
!Balance frágil: la deuda pesa sobre el negocio.
!Crecimiento estancado o en baja.
VALOR1/6FUTURO2/6PASADO3/6SALUD2/6DIVIDENDO5/6
El Iris de calidad
VALOR1/6FUTURO2/6PASADO3/6SALUD2/6DIVIDENDO5/6
ValorCotiza por encima de su valor justo
FuturoCrecimiento moderado
PasadoHistorial aceptable
SaludBalance razonable
DividendoDevuelve capital al accionista
Score Argos37de 100Cara
Ingresos▲4%
US$ 2.9 B
Margen operativo▼16%
12.5%
Flujo de caja libre▼6%
US$ 0.5 B
Deuda neta
US$ 2.6 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 12.7B
P/E52.5x
EV/EBITDA23.2x
FCF yield4%
ROIC3.3%
Margen operativo12.5%
Crecim. ingresos+3.7%/año
Piotroski F7/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 2 jul
Revvity Expands Signals AI With Anthropic Claude Integration
RVTY expands Signals AI through Anthropic's MCP ecosystem, giving scientists secure Claude access to connected R&D data and scientific context.
businesswire.com · 1 jul
Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol (MCP) connectors, enabling scientists to access Signals AI capabilities and connected R&D knowledge through Claude, including Claude Science, Anthropic's new AI workbench for scientific research. As organizations increasingly adopt artificial intelligence to accelerate scientific research, the challenge is ensuring AI mo.
zacks.com · 23 jun
Revvity Launches Signals AI to Advance Scientific R&D Workflows
RVTY expands AI capabilities in Signals software with Signals AI, designed to help scientists turn connected R&D data into actionable insights.
businesswire.com · 22 jun
Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One™ platform, new capabilities from Signals AI help scientists transform connected R&D data into understanding, decisions and action using natural language within their existing workflows. As scientific organizations generate increasing volumes of data acr.
seekingalpha.com · 9 jun
Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
zacks.com · 4 jun
Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?
zacks.com · 14 may
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.
seekingalpha.com · 13 may
Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.